Let’s Talk About CAR T-Cell Therapy as a Treatment Option: Blood Cancers
We invite you to learn more about:
- The process of CAR T-cell therapy
- Eligibility for CAR T-cell therapy
- Side effects and recovery after CAR T-cell therapy
- Maintaining quality of life after CAR T-cell therapy
Monalisa Ghosh, MD
Clinical Associate Professor
University of Michigan Health
Ann Arbor, MI
Program Support
Support for this program is provided by Bristol Myers Squibb; Janssen Oncology & Legend Biotech; and Kite, a Gilead Company.
Coffee With LLS: Let’s Talk About COVID
Please note, with the fast developing knowledge on this topic, some recommendations may change as new data emerges. Click here to access the latest LLS information and resources on COVID-19.
Join LLS as we speak with Dr. Max Brito, professor of medicine in the division of infectious diseases at the University of Illinois at Chicago, Illinois and chief of infectious diseases at the Jesse Brown Veterans Administration Medical Center in Chicago, Illinois. Dr. Brito specializes in the treatment of infectious diseases and in this program he discusses how COVID-19 has affected our blood cancer patients.
This program was originally held in Spanish and has been translated into English.
Max Brito, MD, MPH, FACP, FIDSA
Professor of Medicine
Division of Infectious Diseases
University of Illinois at Chicago (UIC)
Chief of Infectious Diseases
Jesse Brown VA Medical Center
Chicago, Illinois
Program Support
Support for this program provided by BeiGene, Ltd., Bristol Myers Squibb, Kite, A Gilead Company, GSK, Pfizer, and Pharmacyclics, an AbbVie Company & Janssen Biotech.